- Dr. Robert Malone highlights a counterintuitive finding that increased flu vaccination rates among the elderly correlate with higher influenza-related death rates, as shown in a 2005 study. He attributes this to the suppression of natural immunity and misclassification of flu-like illnesses caused by other pathogens.
- Malone warns that annual flu shots may cause “immune imprinting,” where the immune system becomes biased toward older virus strains, reducing its ability to respond effectively to new, evolving flu strains. This undermines the purpose of vaccination.
- He argues that partially effective flu vaccines can accelerate the evolution of vaccine-resistant viruses, making outbreaks harder to control. Malone asserts that imperfect vaccines cannot end influenza outbreaks and may worsen the situation.
- Malone challenges the narrative that the 1918 Spanish flu pandemic was primarily caused by the influenza virus, suggesting most deaths were due to secondary bacterial pneumonia. He advocates for prioritizing antibiotic research over mRNA flu vaccines.
- Unlike the U.S., most countries do not recommend universal flu vaccination. Malone argues that the U.S. approach is driven by the need to sustain vaccine manufacturing capacity rather than public health necessity, calling for transparency and informed consent in vaccination policies.
(Natural News)—In a world where annual flu shots are marketed as a cornerstone of public health, Dr. Robert Malone, a renowned expert in vaccine development, has dropped a bombshell: much of what we’ve been told about influenza vaccination is, in his words, “propaganda.” In a recent essay titled “Deconstructing HHS: Influenza Vaccine Propaganda,” Malone challenges long-standing assumptions about flu vaccines, revealing startling data and historical context that demand a closer look.
The elderly paradox: More vaccines, more deaths?
One of the most shocking revelations in Malone’s essay is the claim that increasing annual influenza vaccination among the elderly is associated with higher influenza-related death rates. This counterintuitive finding is supported by a peer-reviewed study published in Archives of Internal Medicine in 2005. The study analyzed data from 1968 to 2001 and found that as flu vaccine coverage among the elderly rose from 15-20% to 65%, influenza-related mortality rates did not decline as expected.
“Natural immunity acquired by influenza infection works to prevent future ‘influenza-related’ deaths in the elderly,” Malone explains. “Vaccination to a specific influenza A virus strain (H1N1) does not improve natural immunity to that strain and, on average, increased influenza vaccine uptake increases all-cause ‘influenza-related’ death in the elderly.”
This raises serious questions about the efficacy of annual flu shots, particularly for older adults. Malone points out that “influenza-like illness” is often misattributed to the flu virus itself, when in fact, many other pathogens—such as respiratory syncytial virus (RSV), mycoplasma and coronaviruses—can cause similar symptoms. This misclassification inflates flu-related death statistics, much like the controversial “deaths with COVID” versus “deaths from COVID” debate.
Immune imprinting: Are flu shots backfiring?
Another critical issue Malone highlights is the phenomenon of “immune imprinting,” formerly known as “original antigenic sin.” This concept, first described in the 1960s, refers to how the immune system’s first exposure to a virus shapes its response to future infections.
“If you get ‘boosted’ every year with a suboptimal influenza vaccine, it sets your immune system up to be focused on last year’s virus rather than being better able to respond to tomorrow’s strain,” Malone writes. This immune bias can make individuals more susceptible to newly evolved flu strains, undermining the very purpose of vaccination.
This leads to a broader concern: the use of “leaky vaccines,” which are only partially effective at preventing infection and transmission. Malone warns that widespread deployment of such vaccines accelerates the evolution of vaccine-resistant viruses. “You cannot ‘vaccinate’ your way out of an outbreak of influenza with an imperfect vaccine,” he asserts. “If you try, you will only make matters worse.”
A global perspective: Not everyone agrees
Malone notes that most countries do not recommend population-wide annual influenza vaccination. According to a 2016 global review of national immunization policies, only 59% of World Health Organization (WHO) member states have a national flu vaccine policy, and even then, programs typically target high-risk groups rather than the entire population.
This stands in stark contrast to the U.S., where annual flu shots are heavily promoted for nearly everyone over six months old. Malone argues that this approach is driven less by public health necessity and more by the need to maintain influenza vaccine manufacturing capacity.
“You cannot build and mothball an influenza vaccine manufacturing facility for future use,” he explains. “You have to keep making influenza vaccines on a regular basis. And if you are going to make it, you need to have a market for the product.”
A call for transparency and informed consent
Malone’s essay is not an outright condemnation of vaccines but a plea for transparency, rigorous science and respect for individual autonomy. “I am an advocate for sound, well-justified medical practices,” he writes. “Vaccination is a medical procedure, and patients have the right to require informed consent.”
He calls for a shift in public health priorities, away from top-down mandates and toward personalized, physician-guided decision-making. “Making America Healthy Again will require respect for patients and their own personal bodily autonomy,” he concludes.
The bigger picture
Malone’s revelations come at a time when trust in public health institutions is at an all-time low. His essay challenges us to rethink long-held assumptions about flu vaccines and to demand better science, clearer communication and more ethical policies.
As Malone puts it, “Maybe MAHA [Make America Healthy Again] should think this through again?”
The question is: Will we?
Sources include:
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.
